News

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Araverus Team|Wednesday, February 4, 2026 at 1:34 PM

Araverus Team

Feb 4, 2026 · 1:34 PM

AbbVie · Earnings · Immunology Drugs · Revenue Growth

AbbVie Earnings Immunology Drugs Revenue Growth

AbbVie reported higher fourth-quarter revenue driven by strong demand for its immunology drugs Skyrizi and Rinvoq, while also experiencing a smaller decline in sales of its older drug Humira.

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Read More On

Related Articles

Gilead Sciences delivers strong 2025 earnings, plans new cancer and HIV treatments

Leqembi, Cost Cuts Propel Biogen's Profit Outlook Despite MS Sales Decline

Boston Scientific's 16% Sales Growth Fails to Impress as Soft Outlook Spooks Investors

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Read More On

Related Articles

Gilead Sciences delivers strong 2025 earnings, plans new cancer and HIV treatments

Leqembi, Cost Cuts Propel Biogen's Profit Outlook Despite MS Sales Decline

Boston Scientific's 16% Sales Growth Fails to Impress as Soft Outlook Spooks Investors

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development